AstraZeneca halts share repurchases

Shares in drugs giant AstraZeneca were hit in afternoon trading on Monday after the company revealed that it has suspended its share repurchase programme.

After trading in the blue in morning trade, shares swung into negative territory shortly after the announcement, trading down 1.93% at 2,898p by 14:08.

The company has repurchased a net $0.7bn of shares since the end of the first half, bringing the year-to-date total to $2.3bn. The group's initial full-year target for repurchases stands at $4.5bn.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

Chief Executive Officer Pascal Soriot, who was appointed as frontman of the pharmaceuticals mammoth on August 28th, said in a statement: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the board and I complete the company's ongoing annual strategy update."

Nevertheless, the firm reassured that its core earnings per share (EPS) target range for the full year remains at $6.00-6.30.